Scholar Rock Holding Corporation (SRRK) |
|
8.61 -0.54 (-5.9%)
|
03-23 16:00 |
|
Open: |
9.23 |
Pre. Close: |
9.15 |
|
High:
|
9.32 |
Low:
|
8.31 |
|
Volume:
|
234,384 |
Market Cap:
|
448(M) |
|
|
|
Technical analysis |
as of: 2023-03-23 4:25:22 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 11.15 One year: 12.12 |
| Support: |
Support1: 8.2 Support2: 6.82 |
| Resistance: |
Resistance1: 9.54 Resistance2: 10.38 |
| Pivot: |
9.53  |
| Moving Average: |
MA(5): 9.13 MA(20): 9.29
MA(100): 9.44  MA(250): 8.44 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 35.5 %D(3): 43.2 |
| RSI: |
RSI(14): 38.2 |
| 52-week: |
High: 15.31 Low: 4.32 |
| Average Vol(K): |
3-Month: 260 (K) 10-Days: 202 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SRRK ] has closed above bottom band by 2.7%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.34 - 9.39 |
9.39 - 9.45 |
|
Low:
|
8.17 - 8.23 |
8.23 - 8.29 |
|
Close:
|
8.51 - 8.6 |
8.6 - 8.71 |
|
Company Description |
|
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 15 Mar 2023
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Sat, 11 Mar 2023
Equities Analysts Offer Predictions for Scholar Rock Holding Co.'s ... - MarketBeat
Fri, 10 Mar 2023
Why JAKKS Pacific Shares Are Trading Lower By 13%? Here Are ... - Investing.com UK
Wed, 08 Mar 2023
Scholar Rock Holding (NASDAQ:SRRK) shareholders are up 16% this past week, but still in the red over the last year - Simply Wall St
Tue, 07 Mar 2023
Scholar Rock Reports Full Year 2022 Financial Results and ... - Business Wire
Mon, 06 Mar 2023
North American Morning Briefing : Focus This Week -3- - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
52 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
2.8 (%) |
|
% Held by Institutions
|
98.2 (%) |
|
Shares Short
|
2,810 (K) |
|
Shares Short P.Month
|
2,570 (K) |
Stock Financials |
|
EPS
|
-2.81 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.63 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-341.9 |
|
Return on Assets (ttm)
|
-23.2 |
|
Return on Equity (ttm)
|
-54.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.36 |
|
Sales Per Share
|
0.72 |
|
EBITDA (p.s.)
|
-2.41 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-136 (M) |
|
Levered Free Cash Flow
|
-85 (M) |
Stock Valuations |
|
PE Ratio
|
-3.07 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.12 |
|
Price to Sales
|
11.94 |
|
Price to Cash Flow
|
-3.27 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
